Table 2.
Influenza antiviral drugs approved or in clinical trials.
| Antiviral | Mechanism of Action | Clinical Phase and Status | Country of Development/Trial |
|---|---|---|---|
| Das181 (Fludase) | Sialic acid removal in the respiratory airways | II (IFV), III (PIV) not yet recruiting | USA |
| Nitazoxanide | HA maturation inhibition | III completed | USA |
| JNJ-63623872 (Pimodivir) | Small molecule inhibitor of influenza A virus PB2 | III recruiting | Belgium |
| T705 (Favipiravir) | RNA-dependent RNA polymerase inhibitor | IV | Japan |
| Baloxavir marboxil | Small molecule inhibitor of cap-dependent endonuclease (PA) | III recruiting children <1 year 1 | Japan |
| Arbidol (Umifenovir) | HA resistance to conformational changes triggered by pH | III recruiting in China/IV unknown status in Russia | China; Russia |
| Ingavirin | Interaction with NP and inhibition of viral genome release | IV completed | Russia |
Note: Drugs and their clinical statuses were adapted from the clinicaltrials.gov. 1 Approved for treatment of acute uncomplicated influenza among ≥12 years